Mirroring the effects of inhibitors targeting Complex I and glutaminase or glutamine deprivation, alanine supplementation selectively suppressed OXPHOS in SMARCA4/2-deficient cancer cells (Supplementary Fig. 8d–g). Here, GLS is linked to cancer.